ADOCIA Shares Surge 26.46% Over the Week, Boosted by Analyst Recommendation
The Lyon-based company specializing in diabetes and obesity treatments experienced a particularly dynamic week, closing at €9.75 on Friday, October 10. This weekly increase of 26.46% is in stark contrast to the downturns of the CAC 40 and SBF 120, which both fell by approximately 1.7% over the same period.
Significant Surge on Thursday
The week was marked by a significant acceleration on Thursday, October 9, where the stock jumped 35.40% to reach €10.48, before slightly retracting to €9.75 the following day. Trading volumes skyrocketed on this occasion, with more than 2 million shares traded on Thursday, approximately 11% of the company's capital, compared to less than 300,000 shares in previous sessions. This surge is part of a particularly robust medium-term dynamic, with the stock showing a growth of 148.7% over three months and 81.56% over a year, a considerable gap compared to the Parisian indices which have increased by about 4.6% over twelve months. On Friday, despite a 7% decline from the previous day's high, volumes remained strong with 1.36 million shares traded, indicating sustained investor interest.
Sharp Rise Following Analyst Coverage
This sharp rise followed the initiation of coverage by Invest Securities on Thursday, October 9, with the analysis firm setting a buy recommendation and a price target of €17.90. This target price represents an upside potential of over 80% compared to the closing price on Friday, which largely explains the surge in trading volumes observed. Analysts justify their position by the significant potential of the company in the drug delivery technology segment applied to diabetes and obesity, a rapidly expanding market. The peak reached on Thursday at €10.48 now constitutes a technical resistance level to watch, while the support identified at €7.30 remains relatively distant, offering a comfortable margin in case of consolidation.
